ABSTRACT
BACKGROUND AND AIMS: Inflammatory, oxidative stress, and endothelial dysfunction play a key role in the pathogenesis of long-term cardiovascular complications in patients with diabetes. The present observational prospective study is aimed at evaluating the effects of micronutrients and phytochemicals contained in the dietary supplement Flebotrofine® (AMNOL Chimica Biologica) on biochemical markers of inflammation, endothelial dysfunction, and glycemic control in patients with diabetes. METHODS: 105 type 1 or type 2 diabetes patients regularly took a daily dose of the dietary supplement Flebotrofine® for three consecutive months, and haematological and biochemical parameters were checked at baseline, after three months of treatment, and one month after its suspension. Statistical comparison of the laboratory parameters was performed using the two-tailed ANOVA test for repeated samples with a statistical significance level set at p < 0.05. RESULTS: The daily use of Flebotrofine® did not change the glycemic metabolic compensation of enrolled patients. After three months of regular Flebotrofine® intake, the plasma levels of the antioxidant ß-carotene and of arginine were significantly higher compared with the baseline values, with a decrease in the ADMA/arginine ratio. In contrast, apolipoprotein B, ApoB/ApoA1 ratio, and platelet and leukocyte counts significantly dropped. CONCLUSION: The daily use of Flebotrofine® might be a valid supplement of arginine, the precursor of NO, and essential in the prevention of endothelial dysfunction. The regular intake of arginine and phytochemicals also improved the antioxidant and antithrombotic profile of enrolled patients. Therefore, Flebotrofine® could be a useful dietary supplement to prevent long-term complications in patients with diabetes.
Subject(s)
Arginine/administration & dosage , Diabetes Mellitus, Type 2/drug therapy , Diosmin/administration & dosage , Hesperidin/administration & dosage , Hydroxyethylrutoside/analogs & derivatives , Antioxidants/metabolism , Apolipoprotein A-I/metabolism , Apolipoprotein B-100/metabolism , Biomarkers/metabolism , Blood Glucose/drug effects , Diabetes Mellitus, Type 2/metabolism , Dietary Supplements , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Female , Humans , Hydroxyethylrutoside/administration & dosage , Male , Middle Aged , Oxidative Stress/drug effects , Pilot Projects , Prospective StudiesABSTRACT
Cancer is the world's biggest health problem and cancer-induced mortality happened all over the planet after the heart disease. The present study was to scrutinize the anti-leukemia effect of diosmin against Dalton Ascitic Lymphoma (DAL) induced leukemia in mice. DAL cell was used for induction the solid tumor. Body weight, life spans, tumor volume and mean survival time was estimated. Antioxidant, biochemical and pro-inflammatory cytokines were estimated. Diosmin showed the cell viability effect at dose dependent manner against the both cell lines. DAL induced solid tumor mice showed the decreased body weight, mean survival days, non viable cell count and increased the tumor volume, viable cell count and diosmin significantly (p < 0.001) reverse the effect of DAL. Diosmin significantly (p < 0.001) altered the hematological, differential leukocytes, antioxidant, biochemical, pro-inflammatory cytokines at dose dependently. Collectively, we can say that diosmin might alter the DAL induced abnormality via antioxidant and anti-inflammatory effects.
Subject(s)
Anti-Inflammatory Agents , Antineoplastic Agents, Phytogenic , Ascites/pathology , Cell Survival/drug effects , Diosmin/pharmacology , Leukemia/pathology , Lymphoma/pathology , Animals , Antioxidants , Cells, Cultured , Citrus/chemistry , Cytokines/metabolism , Diosmin/administration & dosage , Diosmin/isolation & purification , Dose-Response Relationship, Drug , Inflammation Mediators/metabolism , Leukemia/drug therapy , Leukemia/metabolism , Lymphoma/drug therapy , Lymphoma/metabolism , Mice, Inbred BALB C , PhytotherapyABSTRACT
SARS-CoV-2 or COVID-19 is representing the major global burden that implicated more than 4.7 million infected cases and 310 thousand deaths worldwide in less than 6 months. The prevalence of this pandemic disease is expected to rise every day. The challenge is to control its rapid spread meanwhile looking for a specific treatment to improve patient outcomes. Hesperidin is a classical herbal medicine used worldwide for a long time with an excellent safety profile. Hesperidin is a well-known herbal medication used as an antioxidant and anti-inflammatory agent. Available shreds of evidence support the promising use of hesperidin in prophylaxis and treatment of COVID 19. Herein, we discuss the possible prophylactic and treatment mechanisms of hesperidin based on previous and recent findings. Hesperidin can block coronavirus from entering host cells through ACE2 receptors which can prevent the infection. Anti-viral activity of hesperidin might constitute a treatment option for COVID-19 through improving host cellular immunity against infection and its good anti-inflammatory activity may help in controlling cytokine storm. Hesperidin mixture with diosmin co-administrated with heparin protect against venous thromboembolism which may prevent disease progression. Based on that, hesperidin might be used as a meaningful prophylactic agent and a promising adjuvant treatment option against SARS-CoV-2 infection.
Subject(s)
Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , COVID-19/prevention & control , Hesperidin/therapeutic use , Pandemics/prevention & control , Phytotherapy , SARS-CoV-2/drug effects , Virus Internalization/drug effects , Angiotensin-Converting Enzyme 2/drug effects , Anticoagulants/administration & dosage , Anticoagulants/therapeutic use , COVID-19/complications , COVID-19/epidemiology , Cytokine Release Syndrome/drug therapy , Cytokine Release Syndrome/prevention & control , Diosmin/administration & dosage , Diosmin/therapeutic use , Drug Therapy, Combination , Heparin/administration & dosage , Heparin/therapeutic use , Hesperidin/administration & dosage , Hesperidin/pharmacology , Humans , MAP Kinase Signaling System/drug effects , Receptors, Virus/drug effects , Venous Thromboembolism/etiology , Venous Thromboembolism/prevention & controlABSTRACT
A combination of diosmin and hesperidin (9:1 ratio) is marketed as a dietary supplement/nutraceutical for cardiovascular health. We studied the skeletal effect of this combination (90% diosmin and 10% hesperidin, henceforth named as DH). We showed that a) in rats with femur osteotomy, DH stimulated callus bone regeneration, b) in growing rats, DH promoted peak bone mass achievement and c) in OVX rats rendered osteopenic, DH completely restored femur trabecular bones and strength along with the increases in surface referent bone formation and serum osteogenic marker. Furthermore, DH suppressed bone resorption in OVX rats as well as in OVX rats treated with teriparatide (human parathyroid hormone 1-34) but did not affect the osteoanabolic effect of teriparatide. These data suggested that DH could prolong the anabolic window of teriparatide. To understand the mechanism of DH action, we performed pharmacokinetic studies and observed that upon its oral administration the only circulating metabolites was diosmetin (the aglycone form of diosmin) while none of the two input flavanones were detectable. Accordingly, subsequent experiments with diosmetin revealed that it was a selective estrogen receptor-ß agonist that stimulated osteoblast differentiation and suppressed sclerostin the anti-osteoblastogenic Wnt antagonist. Taken together, our study defined a positive skeletal effect of DH.
Subject(s)
Bone Diseases, Metabolic/prevention & control , Bone Regeneration/drug effects , Diosmin/pharmacology , Hesperidin/pharmacology , Osteogenesis/drug effects , Teriparatide/pharmacology , Animals , Animals, Newborn , Bone Density/drug effects , Bone Diseases, Metabolic/metabolism , Dietary Supplements , Diosmin/administration & dosage , Female , Femur/drug effects , Femur/growth & development , Femur/metabolism , Hesperidin/administration & dosage , Rats, Sprague-Dawley , Teriparatide/administration & dosage , Tibia/drug effects , Tibia/growth & development , Tibia/metabolismABSTRACT
PURPOSE: To assess the effectiveness and safety of a product containing diosmin, coumarin, and arbutin (Linfadren®) in addition to complex decongestive therapy (CDT) on the management of patients with a breast cancer-related lymphedema (BCRL). METHODS: Fifty outpatients (average age of 56.2 ± 2.7 years, range 28-71) with a BCRL were enrolled for this study. Patients were randomly assigned (1:1 ratio) to receive either CDT consisting of skin care, manual lymphatic drainage, remedial exercises, and elastic compression garment (control group, n = 25) or CDT plus Linfadren® (study group, n = 25). Patients were evaluated before and after treatment and 3 months after the end of treatment. Primary outcomes were reduction of upper limb excess volume (EV) and percentage reduction of excess volume (%REV). Secondary outcomes were improvement in Quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH) questionnaire, and patient's perception of treatment effectiveness (PPTE). RESULTS: Addition of Linfadren® to CDT yielded an additional reduction of primary outcomes both after treatment (EV, - 521 ml vs. - 256 ml, P < 0.0001; %REV, - 66.4% vs. - 34%, P = 0.02) and at 3-month follow-up (EV, - 59 ml vs. + 24 ml, P < 0.0001; %REV, - 73.6% vs. - 31.4%, P = 0.004). Moreover, statistically significant differences were found between the two groups for the secondary outcomes after treatment (QuickDASH, P = 0.006; PPTE, P = 0.03) and at 3-month follow-up (QuickDASH, P = 0.006; PPTE, P = 0.02). No patient showed adverse events. CONCLUSIONS: Linfadren® in addition to CDT was a safe and effective therapy for reducing BCRL and was better than CDT alone.
Subject(s)
Arbutin/administration & dosage , Breast Cancer Lymphedema/therapy , Coumarins/administration & dosage , Diosmin/administration & dosage , Adult , Aged , Arbutin/adverse effects , Breast Cancer Lymphedema/epidemiology , Combined Modality Therapy/adverse effects , Compression Bandages/adverse effects , Coumarins/adverse effects , Diosmin/adverse effects , Drainage/adverse effects , Drainage/methods , Exercise Therapy/adverse effects , Exercise Therapy/methods , Female , Humans , Massage/adverse effects , Massage/methods , Middle Aged , Skin Care/adverse effects , Skin Care/methods , Treatment Outcome , Upper ExtremityABSTRACT
In recent years, green nanomedicines have made transformative difference in cancer therapy researches. Herein, we propose dual-functionalized spray-dried casein micelles (CAS-MCs) for combined delivery of two phytochemicals; berberine (BRB) and diosmin (DSN) as targeted therapy of hepatocellular carcinoma (HCC). The nanomicelles enabled parenteral delivery of the poorly soluble DSN via its encapsulation within their hydrophobic core. Moreover, sustained release of the water soluble BRB was attained by hydrophobic ion pairing with sodium deoxycholate followed by genipin crosslinking of CAS-MCs. Dual-active targeting of MCs, via conjugating both lactobionic acid (LA) and folic acid (FA), resulted in superior cytotoxicity and higher cellular uptake against HepG2 cells compared to single-targeted and non-targeted CAS-MCs. The dual-targeted DSN/BRB-loaded CAS-MCs demonstrated superior in vivo anti-tumor efficacy in HCC bearing mice as revealed by down regulation of cell necrosis markers (NF-κB and TNF-α), inflammatory marker COX2, inhibition of angiogenesis and induction of apoptosis. Histopathological analysis and immunohistochemical Ki67 staining confirmed the superiority of the dual-targeted micelles. Ex-vivo imaging showed preferential liver-specific accumulation of dual-targeted CAS-MCs. Overall, this approach combined the benefits of traditional herbal medicine with nanotechnology via LA/FA-CAS-MCs loaded with BRB and DSN as a promising nanoplatform for targeted HCC therapy.
Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Berberine/administration & dosage , Carcinoma, Hepatocellular/drug therapy , Caseins/chemistry , Delayed-Action Preparations/chemistry , Diosmin/administration & dosage , Liver Neoplasms/drug therapy , Animals , Antineoplastic Agents, Phytogenic/therapeutic use , Berberine/therapeutic use , Carcinoma, Hepatocellular/pathology , Diosmin/therapeutic use , Drug Delivery Systems , Hep G2 Cells , Humans , Liver Neoplasms/pathology , Mice , MicellesABSTRACT
BACKGROUND: Venous ulcers are common complications of chronic venous insufficiency that result in severe physical and mental suffering to patients. The oral administration of diosmin/hesperidin has been used as adjuvant therapy in the treatment of chronic venous insufficiency. The purpose of this study was to evaluate and compare the effect of pycnogenol and diosmin/hesperidin on the healing of venous ulcers. METHODS: This longitudinal, prospective, randomized clinical trial was conducted with 30 adult patients with venous ulcers from a vascular surgery outpatient clinic of a university hospital. The patients were randomly allocated to 2 groups: Group 1 (n = 15) was treated with pycnogenol (50 mg orally, 3 times daily) and Group 2 (n = 15) was treated with diosmin/hesperidin (450/50 mg orally, twice daily). They were assessed every 15 days for 90 days. During follow-up visits, photo-documentation was obtained and the ulcer area and circumference of the affected limb were measured. Friedman's test and Mann-Whitney test were used to compare ulcer areas and circumference of affected limbs between and within groups at different time points. The level of significance was set at 5% (P < 0.05) for all tests. RESULTS: Both the pycnogenol and diosmin/hesperidin treatments had a similar effect on the healing of venous ulcers and led to a significant decrease in the circumference of affected limbs (P < 0.0001). CONCLUSION: The results suggest that pycnogenol has an adjuvant effect on the healing of venous ulcers, similar to diosmin/hesperidin.
Subject(s)
Diosmin/therapeutic use , Flavonoids/therapeutic use , Hesperidin/therapeutic use , Varicose Ulcer/drug therapy , Wound Healing/drug effects , Administration, Oral , Aged , Brazil , Diosmin/administration & dosage , Diosmin/adverse effects , Drug Administration Schedule , Drug Combinations , Female , Flavonoids/administration & dosage , Flavonoids/adverse effects , Hesperidin/administration & dosage , Hesperidin/adverse effects , Humans , Longitudinal Studies , Male , Middle Aged , Plant Extracts , Prospective Studies , Time Factors , Treatment Outcome , Varicose Ulcer/diagnosisABSTRACT
The authors analysed the results of examination and treatment of a total of 102 patients presenting with iliofemoral venous thrombosis. During treatment, ultrasonographic duplex scanning was used to determine the localization of the proximal margin of thrombotic masses, the time of appearing of the first signs of recanalization, its degree at various levels of the deep venous system, as well as alteration in velocity of the venous blood flow in the deep veins of the lower limbs. The dynamics of clinical symptoms was assessed by the visual analogue scale. Clinical and instrumental examination was performed on day 10, and then 1, 3, 6 and 12 months after the beginning of treatment. The patients were subdivided into three groups. Group One comprised 38 patients receiving therapy with low-molecular-weight heparin (enoxaprin) followed by switching to indirect anticoagulants (warfarin) combined with venotonics (original highly-purified diosmin 600 mg once daily). Group Two was composed of 33 patients receiving rivaroxaban at a dose of 15 mg twice daily for 3 weeks, followed by 20 mg once daily. Group Tree patients (n=31) were also given rivaroxaban according to the above-described standard regimen but in combination with venotonics (original highly-purified diosmin 600 mg once daily). The obtained findings showed that prescribing rivaroxaban to patients from the first day of the disease made it possible to considerably improve and accelerate the processes of restoration of patency of deep veins of lower extremities as compared with the patients taking vitamin K antagonists (warfarin). In patients receiving rivaroxaban, there were no cases of residual thrombotic occlusions of the major veins, and recanalization in three fourths of patients was assessed as good and in the remaining third as moderate. In the warfarin group, occlusion in the iliac veins was noted to persist persisted in 13% of patients, with good recanalization observed only in half of the patients. Addition of venotonics (original highly-purified diosmin) to anticoagulants from the first day demonstrated safety of this therapeutic regimen (with no cases of clinically significant haemorrhagic complications revealed) and its high efficacy as compared with monotherapy with rivaroxaban. A combination of diosmin with rivaroxaban turned out more efficient than a combination of diosmin with warfarin.
Subject(s)
Femoral Vein , Hemorrhage , Heparin, Low-Molecular-Weight , Iliac Vein , Vascular Patency , Venous Thrombosis , Warfarin , Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Conservative Treatment/methods , Diosmin/administration & dosage , Diosmin/adverse effects , Drug Monitoring/methods , Drug Therapy, Combination/methods , Female , Femoral Vein/diagnostic imaging , Femoral Vein/pathology , Hemorrhage/chemically induced , Hemorrhage/diagnosis , Heparin, Low-Molecular-Weight/administration & dosage , Heparin, Low-Molecular-Weight/adverse effects , Humans , Iliac Vein/diagnostic imaging , Iliac Vein/pathology , Lower Extremity/blood supply , Male , Middle Aged , Retrospective Studies , Rivaroxaban/administration & dosage , Rivaroxaban/adverse effects , Russia , Treatment Outcome , Ultrasonography, Doppler, Duplex/methods , Venous Thrombosis/diagnosis , Venous Thrombosis/drug therapy , Venous Thrombosis/physiopathology , Visual Analog Scale , Warfarin/administration & dosage , Warfarin/adverse effectsSubject(s)
Diosmin/therapeutic use , Hesperidin/therapeutic use , Pregnancy Complications, Cardiovascular/drug therapy , Proanthocyanidins/therapeutic use , Venous Thrombosis/drug therapy , Vitis , Diosmin/administration & dosage , Female , Gynecology/standards , Hesperidin/administration & dosage , Humans , Inservice Training/standards , National Health Programs/standards , Obstetrics/standards , Plant Leaves , Poland , Pregnancy , Pregnancy Complications, Cardiovascular/prevention & control , Proanthocyanidins/administration & dosage , Quality Assurance, Health Care/standards , Societies, Medical/standards , Venous Thrombosis/prevention & control , Women's HealthABSTRACT
OBJECTIVE: The present study was undertaken to evaluate the effect of diosmin in diabetic neuropathy in type 2 diabetic rats. METHODS: Type 2 diabetes was induced in male Sprague-Dawley rats by single intraperitoneal injection of streptozotocin (35 mg/kg) and high-fat diet. Four weeks after the confirmation of diabetes, diabetic rats were treated with diosmin (50 and 100 mg/kg, p.o.) for next 4 weeks. Rats were evaluated for biochemical, behavioral and oxidative stress parameters. Eddy's hot plate and tail immersion test were performed on 6th, 7th, 8th, 9th and 10th weeks of experiment to assess thermal hyperalgesia and cold allodynia respectively. Further, the walking function test was performed for assessing the motor responses at the end of the treatment schedule. RESULTS: Rats were fed with high-fat diet throughout the experiment schedule and administration of low-dose streptozotocin induced significant elevation in blood glucose level and insulin resistance which was confirmed by oral glucose tolerance test. Treatment with diosmin at doses of 50 and 100 mg/kg significantly restored the reduced body weight, elevated blood sugar and lipid profiles. Further the dose-dependent improvement was observed in thermal hyperalgesia, cold allodynia and walking function in diabetic rats treated with diosmin. Elevated levels of malondialdehyde, and nitric oxide and decreased glutathione levels and superoxide dismutase activity in diabetic rats were restored significantly after the 4 weeks of diosmin treatment. CONCLUSION: Diosmin has shown beneficial effect in preventing the progression of early diabetic neuropathy in rats.
Subject(s)
Diabetic Neuropathies/prevention & control , Diosmin/administration & dosage , Plant Extracts/administration & dosage , Animals , Blood Glucose/metabolism , Cholesterol/metabolism , Citrus/chemistry , Diabetic Neuropathies/drug therapy , Diabetic Neuropathies/metabolism , Glutathione/metabolism , Humans , Male , Malondialdehyde/metabolism , Oxidative Stress/drug effects , Rats , Rats, Sprague-DawleyABSTRACT
PURPOSE: To evaluate long-term follow-up of the orally administered combination of flavonoids with Centella asiatica and Melilotus for treatment of diabetic cystoid macular edema (CME) without macular thickening. METHODS: Seventy consecutive patients with type 2 diabetes and CME without macular thickening at optical coherence tomography (OCT) were prospectively and randomly enrolled in two groups of 35 subjects each (treatment and control groups). Patients in the treatment group were treated with an oral combination of diosmin (300 mg/day), with C. asiatica (15 mg/day) and Melilotus (160 mg/day). All patients underwent a complete ophthalmologic examination, OCT (Spectralis HRA-OCT), and central microperimetry (SD-SLO/OCT) at baseline, month 3, month 6, month 12, month 24, and month 36. RESULTS: No differences in HbAc1 percentage, blood pressure, microalbuminuria, visual acuity, mean central retinal thickness, and stability of fixation were present between the two groups during follow up (p>0.05). Retinal sensitivity reduced in the control group only from month 6 until month 36 (p<0.001). In the treatment group, a greater retinal sensitivity was present at month 12, month 24, and month 36 (p=0.001). No side effects of treatment were observed. CONCLUSION: Oral administration of flavonoids, C. asiatica and Melilotus, in patients with CME without macular thickening provided preservation of retinal sensitivity during 36 months of follow up when compared with untreated patients.
Subject(s)
Centella/chemistry , Diabetes Complications/drug therapy , Diosmin/therapeutic use , Macular Edema/drug therapy , Melilotus/chemistry , Plant Preparations/therapeutic use , Administration, Oral , Aged , Diabetes Complications/etiology , Diabetes Complications/physiopathology , Diosmin/administration & dosage , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Macular Edema/etiology , Macular Edema/physiopathology , Male , Middle Aged , Plant Preparations/administration & dosage , Prospective Studies , Treatment Outcome , Visual Acuity/drug effectsABSTRACT
Presented in the article are the findings of a multicenter prospective clinical trial assessing quality of life of patients with chronic diseases of lower limb veins on the background of administration of nonmicronized diosmin (Vasocet). Specialized questionnaires (CIVIQ-2) appeared to be the most optimal evaluating tools, more precisely catching alterations in patients' quality of life on the background of drug therapy.
Subject(s)
Dietary Supplements/adverse effects , Diosmin , Lower Extremity/blood supply , Venous Insufficiency , Adult , Chronic Disease , Diosmin/administration & dosage , Diosmin/adverse effects , Female , Humans , Male , Middle Aged , Outcome Assessment, Health Care , Pain/diagnosis , Pain/etiology , Pain/physiopathology , Pain Measurement/methods , Patient Satisfaction , Quality of Life , Surveys and Questionnaires , Treatment Outcome , Ultrasonography , Veins/diagnostic imaging , Veins/drug effects , Venous Insufficiency/complications , Venous Insufficiency/diagnosis , Venous Insufficiency/drug therapy , Venous Insufficiency/physiopathology , Venous Insufficiency/psychologyABSTRACT
OBJECTIVE: To establish a HPLC method for the determination of diosmin in Rats plasma and to study the pharmacokinetics of diosmin in Rats. METHOD: Rats were given diosmin with 3 doses as 225, 325, 425 mg x kg(-1). Blood samples were collected at different times after oral administration. The plasma concentration of diosmin was determined by HPLC, and the pharmacokinetics parameters were calculated by 3p97 program. RESULT: The typical equation of diosmin in rats plasma was Y = 3.05 x 10(-3) C + 1.55 x 10(-3), the calibration curves of diosmin was linear in the range from 0.5-100 microg x mL(-1) (R =0. 996 4). The lowest concentration of diosmin in plasma was 0. 2 g x mL(-1). Its recoveries was more than 85%, and the interday and intraday precision, which was expressed as RSD, were all less than 15%. After 3 doses oral administration of diosmin in rats, the mean plasma concentration-time curves were found to fit one compartment model, and the main pharmacokinetics parameters were obtained. CONCLUSION: It is first time to establish the HPLC method to determine the concentration of diosmin in rats plasma, and the method described in this report has high sensitivity and selectivity, and it was suitable for pharmacokinetics studies of diosmin. The internal process of diosmin in rats is fit to one compartment model.
Subject(s)
Diosmin/blood , Diosmin/pharmacokinetics , Administration, Oral , Animals , Area Under Curve , Chromatography, High Pressure Liquid , Diosmin/administration & dosage , Female , Male , Plants, Medicinal/chemistry , Rats , Rats, WistarABSTRACT
The aim of this study was to investigate the clinical efficacy of oral Pycnogenol (Horphag Research Ltd., UK) in patients with severe chronic venous insufficiency (CVI) in comparison to the combination of diosmin and hesperidin (Daflon, Servier, France). A group of 86 patients with severe chronic venous insufficiency (CVI), venous hypertension, ankle swelling) and previous history of venous ulcerations received either oral Pycnogenol (capsules) 150 mg or 300 mg daily for 8 weeks or Daflon, 1,000 mg/day. All patients completed the study without dropouts. At the end of the study, microcirculatory results indicated: a progressive decrease of skin flux at rest (RF); a significant decrease in capillary filtration (RAS); an improvement in the symptomatic venous score (ASLS); a reduction in edema; a significant improvement (increase) in pO(2) and a decrease in pCO(2) in the Pycnogenol group. A significant level of improvement was reached after 4 weeks of treatment in most patients (p < .05) of the Pycnogenol group while clinical improvement was significant only in 6 subjects in the Daflon group. The positive effects of treatment with Pycnogenol after 8 weeks were significantly larger in comparison with the Daflon group. In conclusion, this study confirms the fast clinical efficacy of Pycnogenol in patients with chronic venous insufficiency and venous microangiopathy and its superiority-considering the evaluated parameters-to the combination of diosmin and hesperidin.
Subject(s)
Diosmin/administration & dosage , Flavonoids/administration & dosage , Venous Insufficiency/drug therapy , Adult , Blood Gas Analysis , Chronic Disease , Edema/drug therapy , Humans , Hypertension/drug therapy , Middle Aged , Plant Extracts , Treatment Outcome , Varicose Ulcer/drug therapyABSTRACT
OBJECTIVE: To study the effect of different phenolic compounds and red wine on pulmonary metastatic melanoma. METHODS: Swiss mice were inoculated with 500000 melanocytes B16F10 and given oral doses of diosmin, grape seed extract (GSE) and red wine. A macroscopic count was made of the metastatic nodules on the lung surface and a microscopic study by image analysis of five sections, calculating the implantation percentage and tumoral growth and invasion indices. RESULTS: Macroscopically, the group treated with diosmin showed the greatest reduction (52%) in the number of metastatic nodules compared with the control group, which was treated with ethanol, while GSE and red wine caused decreases of 26.07 and 28.81%, respectively. Microscopically, there was a decrease in the implantation percentage after the administration of diosmin (79.4%) and red wine (20.19%), and an increase of 2.12% after the administration of GSE, all relative to the ethanol-treated control. As regards the growth index, diosmin produced a reduction of 67.44% and red wine a reduction of 20.62%, while GSE again produced an increase (25.33%). The reductions in the invasion index were 45.23, 31.65 and 17.57% with diosmin, GSE and red wine, respectively. CONCLUSIONS: Diosmin originated the greatest reduction in pulmonary metastases, both at the macroscopic and microscopic levels.
Subject(s)
Diosmin/pharmacology , Lung Neoplasms/secondary , Melanoma, Experimental/drug therapy , Phytotherapy , Plant Extracts/pharmacology , Vitis , Wine , Administration, Oral , Animals , Diosmin/administration & dosage , Female , Lung Neoplasms/prevention & control , Melanocytes/pathology , Melanocytes/transplantation , Melanoma, Experimental/pathology , Mice , Neoplasm Invasiveness/pathology , Neoplasm Transplantation , Phytotherapy/methods , Plant Extracts/administration & dosage , SeedsABSTRACT
In this study, we have evaluated the efficacy of dosmalfate, a new flavonoid derivative compound, for the prevention and treatment of experimental colitis. To induce colitis, BALB/c mice received 5% dextran sulphate sodium (DSS) in their drinking water continuously for 7 days. Colitis was quantified by a clinical damage score, colon length, weight loss, stool consistency and rectal bleeding. Inflammatory response was assessed by neutrophil infiltration, determined by histology and myeloperoxidase (MPO) activity. Interleukin (IL)-1 beta, prostaglandins (PG)E(2) and (PG)D(2) concentrations in colonic tissue, histological and histochemical analysis of the lesions were also measured. Dosmalfate (400-800 mg/kg body weight, p.o.) ameliorated severe colitis reduced the degree of inflammation through reduction of neutrophil infiltration and IL-1 beta levels. (PG)E(2) and (PG)D(2) synthesis were significantly reduced in colitis control group and treatment with dosmalfate abolished the decrease in PG synthesis in colon mucosa. We conclude that dosmalfate is protective in acute DSS-induced colitis. The beneficial effects seem to be related to a decrease of neutrophil infiltration, absence of up-regulation of IL-1 beta and increase of PG production in colon mucosa.
Subject(s)
Colitis, Ulcerative/chemically induced , Dextran Sulfate/adverse effects , Dextran Sulfate/antagonists & inhibitors , Diosmin/analogs & derivatives , Diosmin/therapeutic use , Administration, Oral , Animals , Colitis, Ulcerative/drug therapy , Colon, Descending/drug effects , Colon, Descending/injuries , Colon, Descending/ultrastructure , Colon, Transverse/drug effects , Colon, Transverse/injuries , Colon, Transverse/ultrastructure , Dextran Sulfate/administration & dosage , Dinoprostone/biosynthesis , Diosmin/administration & dosage , Diosmin/pharmacokinetics , Disease Models, Animal , Drinking , Flavonoids/administration & dosage , Flavonoids/chemistry , Flavonoids/pharmacokinetics , Interleukin-1/biosynthesis , Intestinal Mucosa/drug effects , Intestinal Mucosa/enzymology , Intestinal Mucosa/injuries , Male , Mice , Mice, Inbred BALB C , Neutrophil Infiltration/drug effects , Peroxidase/metabolism , Prostaglandin D2/biosynthesis , Time Factors , WaterABSTRACT
PURPOSE: The aim of this study was to assess the role of micronized purified flavonidic fraction in the management of bleeding nonprolapsed hemorrhoids. METHODS: Patients were randomly assigned to receive ispaghula husk alone, rubber band ligation plus ispaghula husk, or micronized purified flavonidic fraction plus ispaghula husk. Other colorectal diseases were excluded by colonoscopy. Blinded observers noted the time for bleeding to stop completely, recurrences, and treatment complications. RESULTS: A total of 162 patients were randomly assigned with no significant differences in the age and gender distributions among the groups. Hemorrhoidal bleeding was relieved most expediently in the micronized purified flavonidic fraction plus ispaghula husk group (ispaghula husk alone n = 66, mean (standard error of the mean) 10.6 (2.3) days; rubber band ligation plus ispaghula husk n = 57, 5.6 (1.1) days; micronized purified flavonidic fraction plus ispaghula husk n = 39, 3.9 (1.2) days; P = 0.03). However, there were no significant differences in the recurrences at six months of follow-up (ispaghula husk alone n = 8 (12 percent); rubber band ligation plus ispaghula husk n = 12 (21 percent); micronized purified flavonidic fraction plus ispaghula husk n = 2 (5.1 percent); P = 0.075). No complications or side-effects were noted. CONCLUSIONS: micronized purified flavonidic fraction used with fiber supplements rapidly and safely relieved bleeding from nonprolapsed hemorrhoids.